Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study

European Heart Journal

Volumn 19, Issue SUPPL.D, 1998, Pages

  Van Hout, B A ^a   Bowman, L ^a   Zelinger, D J ^a   Simoons, M L ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST;

CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HEALTH CARE COST; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY DISEASE; COST-BENEFIT ANALYSIS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; UNITED STATES;

EID: 0031919805     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)